TAMPA, Fla., Aug. 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second quarter 2025 results that mark a decisive step forward in its turnaround strategy.
The Company delivered substantial quarterly year-over-year improvements across key financial metrics:
"We believe that our turnaround is real and accelerating," said Damien Lamendola, Chief Executive Officer of Marpai. "In just one year, we have significantly strengthened our financial position by cutting costs, streamlining operations, and staying laser-focused on profitability. We estimate that we are on track to deliver a profitable company in the first quarter of 2026. Our pipeline of new business for January 1st 2026 is strong, and we expect to make a major infrastructure investment in Q3 to further improve efficiency and client service. I believe deeply in Marpai's future. That's why I continue to invest my own personal capital in the company.
While net revenues for the quarter were $4.7 million, down $2.5 million from the same quarter last year due to transitional impacts, the Company's sharp focus on cost control and operational discipline has resulted in a much leaner, stronger platform for growth."
Webcast and Conference Call Information
Marpai expects to host a conference call and webcast on Thursday, August 14, 2025, at 8:30 a.m. ET to review the Company's operational and financial highlights for its second quarter ended June 30, 2025.
Investors interested in listening to the conference call may do so by dialing (800)-836-8184 for domestic callers or +1-646-357-8785 for international callers, or via webcast: https://app.webinar.net/pD32GbLd5Mx
About Marpai, Inc.
Marpai, Inc. (OTCQX: MRAI) is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $150 billion TPA sector serving self-funded employer health plans representing over $1.5 trillion in annual claims. Through its Marpai Saves initiative, the Company works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. Investors are invited to visit https://ir.marpaihealth.com.
Forward-Looking Statement Disclaimer
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance," "may," "can," "could", "will", "potential", "should," "goal" and variations of these words or similar expressions. For example, the Company is using forward-looking statements when it discusses that it continues to make strong progress with its turnaround efforts, that improvements in its operating expenses and bottom line signals a critical inflection point for the Company, that it expects to make a major infrastructure investment in the third quarter, its belief that it is on track to achieve profitability in the first quarter of 2026 and that its focus on cost control and operational discipline has resulted in a much leaner, stronger platform for growth. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect Marpai's current expectations and speak only as of the date of this release. Actual results may differ materially from Marpai's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business. Except as required by law, Marpai does not undertake any responsibility to revise or update any forward-looking statements whether as a result of new information, future events or otherwise.
More detailed information about Marpai and the risk factors that may affect the realization of forward-looking statements is set forth in Marpai's filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
MARPAI, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) | ||||||||
June 30, | December 31, | |||||||
(Unaudited) | ||||||||
ASSETS: | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 619 | $ | 764 | ||||
Restricted cash | 7,661 | 8,468 | ||||||
Accounts receivable, net of allowance for credit losses of $1 and $1 as of June 30, 2025, and December 31, 2024, respectively | 548 | 837 | ||||||
Unbilled receivables | 914 | 569 | ||||||
Due from buyer for sale of business unit | — | 500 | ||||||
Prepaid expenses and other current assets | 590 | 759 | ||||||
Total current assets | 10,332 | 11,897 | ||||||
Capitalized software, net | 227 | 441 | ||||||
Operating lease right-of-use assets | 265 | 296 | ||||||
Security deposits | 229 | 229 | ||||||
Other long-term asset | 8 | 15 | ||||||
Total assets | $ | 11,061 | $ | 12,878 | ||||
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,588 | $ | 3,109 | ||||
Accrued expenses | 2,069 | 2,585 | ||||||
Accrued fiduciary obligations | 7,179 | 6,308 | ||||||
Deferred revenue | 743 | 625 | ||||||
Current portion of operating lease liabilities | 250 | 244 | ||||||
Current portion of convertible debentures, net | 3,037 | 3,106 | ||||||
Other short-term liabilities | 2,868 | 3,005 | ||||||
Total current liabilities | 19,734 | 18,982 | ||||||
Other long-term liabilities | 15,719 | 14,891 | ||||||
Convertible debentures, net of current portion | 7,311 | 5,921 | ||||||
Operating lease liabilities, net of current portion | 664 | 793 | ||||||
Total liabilities | 43,428 | 40,587 | ||||||
COMMITMENTS AND CONTINGENCIES (Note 16) | ||||||||
STOCKHOLDERS' DEFICIT | ||||||||
Common stock, $0.0001 par value, 227,791,050 shares authorized; 16,536,186 shares and | 2 | 1 | ||||||
Additional paid-in capital | 73,905 | 71,124 | ||||||
Accumulated deficit | (106,274) | (98,834) | ||||||
Total stockholders' deficit | (32,367) | (27,709) | ||||||
Total liabilities and stockholders' deficit | $ | 11,061 | $ | 12,878 | ||||
MARPAI, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except share and per share data) | ||||||||||||||||
Three months ended | Six months ended | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Revenue | $ | 4,656 | $ | 7,189 | $ | 10,074 | $ | 14,574 | ||||||||
Costs and expenses | ||||||||||||||||
Cost of revenue (exclusive of depreciation and amortization shown separately below) | 3,910 | 5,174 | 7,395 | 10,045 | ||||||||||||
General and administrative | 2,483 | 3,721 | 4,766 | 7,142 | ||||||||||||
Information technology | 1,291 | 1,210 | 2,681 | 2,334 | ||||||||||||
Sales and marketing | 312 | 436 | 556 | 1,038 | ||||||||||||
Research and development | — | 8 | 7 | 15 | ||||||||||||
Depreciation and amortization | 107 | 914 | 214 | 1,865 | ||||||||||||
Impairment of goodwill and intangible assets | — | 7,588 | — | 7,588 | ||||||||||||
Facilities | 160 | 411 | 311 | 885 | ||||||||||||
Total costs and expenses | 8,263 | 19,462 | 15,930 | 30,912 | ||||||||||||
Operating loss | (3,607) | (12,273) | (5,856) | (16,338) | ||||||||||||
Other income (expenses) | ||||||||||||||||
Other income | 49 | 120 | 49 | 240 | ||||||||||||
Interest expense, net | (813) | (872) | (1,633) | (1,270) | ||||||||||||
Foreign exchange loss | — | (1) | — | (4) | ||||||||||||
Loss before provision for income taxes | (4,371) | (13,026) | (7,440) | (17,372) | ||||||||||||
Income tax expense | — | — | — | — | ||||||||||||
Net loss | $ | (4,371) | $ | (13,026) | $ | (7,440) | $ | (17,372) | ||||||||
Net loss per share, basic and fully diluted | $ | (0.28) | $ | (1.23) | $ | (0.49) | $ | (1.73) | ||||||||
Weighted average shares of common stock outstanding, basic and diluted | 15,503,132 | 10,626,516 | 15,140,332 | 10,016,146 | ||||||||||||
MARPAI, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) | ||||||||
Six months ended | ||||||||
2025 | 2024 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (7,440) | $ | (17,372) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 214 | 1,865 | ||||||
Loss on sale of receivables | — | 306 | ||||||
Share-based compensation | 1,043 | 2,421 | ||||||
Amortization of right-of-use asset | 31 | 120 | ||||||
Non-cash interest | 914 | 646 | ||||||
Amortization of debt premium and debt issuance costs | (17) | 62 | ||||||
Impairment of goodwill and intangible assets | — | 7,588 | ||||||
Issuance of common stock to vendors in exchange for services | 1,008 | — | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable and unbilled receivables | (56) | 519 | ||||||
Prepaid expenses and other assets | 176 | (66) | ||||||
Accounts payable | 479 | (1,477) | ||||||
Accrued expenses | (516) | (173) | ||||||
Accrued fiduciary obligations | 871 | (1,625) | ||||||
Operating lease liabilities | (123) | (250) | ||||||
Other liabilities | 92 | 731 | ||||||
Net cash used in operating activities | (3,324) | (6,705) | ||||||
Cash flows from investing activities: | ||||||||
Proceeds from sale of business unit | 500 | — | ||||||
Net cash provided by investing activities | 500 | — | ||||||
Cash flows from financing activities: | ||||||||
Proceeds from sale of future cash receipts on accounts receivable | — | 1,509 | ||||||
Proceeds from issuance of convertible debentures (Note 7) | 3,000 | 5,978 | ||||||
Payments of debt issuance costs | (162) | (499) | ||||||
Payments to buyer of receivables | — | (1,816) | ||||||
Payments on convertible debentures (Note 7) | (1,500) | — | ||||||
Payments to seller for acquisition | (196) | (631) | ||||||
Proceeds from issuance of common stock in a private offering, net | 730 | 2,727 | ||||||
Net cash provided by financing activities | 1,872 | 7,268 | ||||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (952) | 563 | ||||||
Cash, cash equivalents and restricted cash at beginning of period | 9,232 | 13,492 | ||||||
Cash, cash equivalents and restricted cash at end of period | $ | 8,280 | $ | 14,055 | ||||
Reconciliation of cash, cash equivalents, and restricted cash reported in the | ||||||||
Cash and cash equivalents | $ | 619 | $ | 1,293 | ||||
Restricted cash | 7,661 | 12,762 | ||||||
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statement of cash flows | $ | 8,280 | $ | 14,055 | ||||
Supplemental disclosure of cash flow information | ||||||||
Cash paid for interest | $ | 781 | $ | 1,259 | ||||
| Last Trade: | US$1.38 |
| Daily Change: | -0.02 -1.43 |
| Daily Volume: | 100 |
| Market Cap: | US$21.070M |
May 14, 2025 May 13, 2025 March 18, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
